Elevated ctDNA Tumor Fraction Is Associated with Improved Mutation Detection but Worse Overall Survival in Advanced Non-Small Cell Lung Cancer: A Lung-MAP Study.

doi:10.1158/1078-0432.CCR-24-3658

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Elevated ctDNA Tumor Fraction Is Associated with Improved Mutation Detection but Worse Overall Survival in Advanced Non-Small Cell Lung Cancer: A Lung-MAP Study.

Clinical cancer research : an official journal of the American Association for Cancer Research - 14 Aug 2025

Mack Philip C, Redman Mary W, Tukachinsky Hanna, Kozono David E, Minichiello Katherine, Dragnev Konstantin H, Tolba Khaled A, Neal Joel W, Madison Russell W, Waqar Saiama N, Aggarwal Charu, Hirsch Fred R, Patel Jyoti D, Herbst Roy S, Chiang Anne C, Reckamp Karen L, Kelly Karen, Borghaei Hossein, Gray Jhanelle E, Gandara David R

Abstract excerpt

PURPOSE: ctDNA is a powerful diagnostic companion to tissue profiling. Tumor fraction (TF) is a global assessment of an individual's ctDNA burden. We evaluated the impact of plasma TF on mutation detection and clinical outcomes in patients with previously treated, advanced non-small cell lung cancer on the Lung Master Protocol (Lung-MAP). EXPERIMENTAL DESIGN: Paired tumor tissue and plasma were collected...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biomarkers, Tumor

Share to Carcinoma, Non-Small-Cell Lung

Share to Circulating Tumor DNA

Share to Gene Frequency

Share to Lung Neoplasms

Share to Neoplasm Staging

Share to Prognosis

Source

Open in PubMed Open full text

Identifiers

PMID: 40465842
DOI: 10.1158/1078-0432.CCR-24-3658
PMCID: PMC12842961

Genes

TF
KRAS
STK11
TP53

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Elevated ctDNA Tumor Fraction Is Associated with Improved Mutation Detection but Worse Overall Survival in Advanced Non-Small Cell Lung Cancer: A Lung-MAP Study.PMID 40465842Read ↗

Measurement of ctDNA Tumor Fraction Identifies Informative Negative Liquid Biopsy Results and Informs Value of Tissue Confirmation.Semantic proximity Read ↗

Capture-Based Targeted Ultradeep Sequencing in Paired Tissue and Plasma Samples Demonstrates Differential Subclonal ctDNA-Releasing Capability in Advanced Lung Cancer.Semantic proximity Read ↗

Clinical application of the Lung Cancer Compact PanelTM using various types of cytological specimens in patients with lung cancer.Semantic proximity Read ↗

Profiling Cell-Free DNA from Malignant Pleural Effusion for Oncogenic Driver Mutations in Patients with Treatment-Naive Stage IV Adenocarcinoma: A Multicenter Prospective Study.Semantic proximity Read ↗

Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients.Semantic proximity Read ↗

Tumor-derived DNA from pleural effusion supernatant as a promising alternative to tumor tissue in genomic profiling of advanced lung cancerSemantic proximity Read ↗

Advancing Evidence Generation for Circulating Tumor DNA: Lessons Learned from A Multi-Assay Study of Baseline Circulating Tumor DNA Levels across Cancer Types and StagesSemantic proximity Read ↗

Tumor Fraction Correlates With Detection of Actionable Variants Across > 23,000 Circulating Tumor DNA SamplesSemantic proximity Read ↗

Pre-radiotherapy ctDNA liquid biopsy for risk stratification of oligometastatic non-small cell lung cancerSemantic proximity Read ↗

Clinical Validity and Utility of Circulating Tumor DNA (ctDNA) Testing in Advanced Non-small Cell Lung Cancer (aNSCLC): A Systematic Literature Review and Meta-analysis.Semantic proximity Read ↗

Combining tumor genomic and transcriptomic analysis with liquid biopsy ctDNA monitoring: analytical validation and clinical insightsSemantic proximity Read ↗

Plasma biopsy by Tag-sequencing: an acceptable alternative to tumor tissue profiling in non-small-cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.